{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:24:23Z","timestamp":1788805463571,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vph.2025.107550","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T03:23:10Z","timestamp":1760066590000},"page":"107550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: A systematic review and meta-analysis with trial sequential analysis"],"prefix":"10.1016","volume":"161","author":[{"given":"Laila","family":"Shalabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar M.","family":"Al Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofian","family":"Zreigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuelazm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2025.107550_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.vph.2025.107550_bb0010","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2147\/PPA.S368784","article-title":"A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider","volume":"16","author":"Hamrahian","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.vph.2025.107550_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1211199","article-title":"When blood pressure refuses to budge: exploring the complexity of resistant hypertension","volume":"10","author":"Champaneria","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.vph.2025.107550_bb0020","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1038\/s41598-018-27377-2","article-title":"Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III linked mortality study","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2025.107550_bb0025","doi-asserted-by":"crossref","unstructured":"Li ECK, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst. Rev. 2014;2014:CD009096. doi: https:\/\/doi.org\/10.1002\/14651858.CD009096.pub2.","DOI":"10.1002\/14651858.CD009096.pub2"},{"key":"10.1016\/j.vph.2025.107550_bb0030","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2025.107550_bb0035","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2025.107550_bb0040","first-page":"23","article-title":"Primary aldosteronism and resistant hypertension: a pathophysiological insight","author":"Bioletto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vph.2025.107550_bb0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/VHRM.S138599","article-title":"Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists","volume":"13","author":"Yugar-Toledo","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.vph.2025.107550_bb0050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1159\/000542621","article-title":"Aldosterone synthase inhibitors for cardiorenal protection: ready for prime time?","volume":"49","author":"Mazzieri","year":"2024","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.vph.2025.107550_bb0055","article-title":"Emerging therapies for treatment-resistant hypertension: a review of Lorundrostat and related selective aldosterone synthase inhibitors","author":"Feldman","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.vph.2025.107550_bb0060","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2025.107550_bb0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2025.107550_bb0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"10.1016\/j.vph.2025.107550_bb0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.vph.2025.107550_bb0080","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2025.107550_bb0085","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2025.107550_bb0090","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"257","article-title":"Analyzing data and undertaking meta-analyses","author":"Higgins","year":"2019"},{"key":"10.1016\/j.vph.2025.107550_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.vph.2025.107550_bb0100","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2025.107550_bb0105","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2025.107550_bb0110","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.vph.2025.107550_bb0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/HJH.0000000000001914","article-title":"Different effects of antihypertensive treatment on office and ambulatory blood pressure: a meta-analysis","volume":"37","author":"Soranna","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2025.107550_bb0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archinte.162.5.582","article-title":"Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni","volume":"162","author":"Mancia","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.vph.2025.107550_bb0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","article-title":"Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016","volume":"129","author":"Epstein","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.vph.2025.107550_bb0130","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJMcp1901117","article-title":"Acute severe hypertension","volume":"381","author":"Peixoto","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2025.107550_bb0135","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.jacc.2017.11.004","volume":"71","author":"Reboussin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2025.107550_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.vph.2025.107550_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MNH.0000000000001067","article-title":"Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors","volume":"34","author":"Helmeczi","year":"2025","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.vph.2025.107550_bb0150","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2025.107550_bb0155","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.vph.2025.107550_bb0160","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.vph.2025.107550_bb0165","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.kint.2016.11.019","article-title":"Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications","volume":"91","author":"Weir","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.vph.2025.107550_bb0170","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125000898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125000898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:01:51Z","timestamp":1781208111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189125000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"alternative-id":["S1537189125000898"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2025.107550","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: A systematic review and meta-analysis with trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2025.107550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107550"}}